ClinicalTrials.gg
CompletedNCT03604328Updated Sep 16, 2020

Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma

A Phase 1 interventional study of PA5108 in Open-angle Glaucoma, sponsored by PolyActiva Pty Ltd. Completed at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by PolyActiva Pty Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Glaucoma, Open-Angle with a site in Australia — none open to participants now, 2 under way, none of them phase 3. Glaucoma, Open-Angle · Australia.

Enrollment
14th of 14
8 · median 84
Started
2018
with 1 other
Phase 1
4 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
3 of 14
PolyActiva Pty Ltd

Among the 14 studies in Glaucoma, Open-Angle with a site in Australia, this one is the 14th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 1, and was the 7th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 14 studies in Glaucoma, Open-Angle with a site in Australia is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Glaucoma, Open-Angle with a site in Australia as a file.
02

Study summary

A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).

Read the detailed description

Participants who are currently managing their Open Angle Glaucoma with combination drop therapy will be recruited. Drop therapy will cease in the treatment eye and continue in the contralateral eye. The treated eye will receive via injection, a single PA5108 ocular implant. Participants will be monitored for safety and tolerability of the ocular implant until it completely biodegrades.

03

Conditions studied

  • Open-angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Grade 3 or 4 open angle glaucoma (Shaffer-Etienne scale)
  • Visual acuity in non-study eye same or better than study eye
  • Currently taking topical ocular hypotensive medication including a prostaglandin analogue

Exclusion criteria

Exclusion Criteria:

  • Aphakic eyes
  • Only one eye
  • History of, or current uveitis, Cystoid Macular Edema (CME) or cornea edema
  • Intraocular surgery or cornea/refractive surgery in study eye in past 6 months or anticipate need for eye surgery (including laser) in study eye during study period
  • Current retinal detachment
  • Uncontrolled infection in the eye
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    PA5108

    PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)

    Drug: PA5108

Interventions

  • DrugPA5108

    single ocular implant, administered on day 1

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as measured by the occurrence of adverse events

    Time frame: 4 weeks

Secondary outcomes

  1. Timeframe to complete implant biodegradation based on implant size and location

    Time frame: 6 months

07

Study locations

2 sites
  • Centre for Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Melbourne Eye Specialists
    Melbourne, Victoria 3000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jun 2020, 22 months.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Jul 27, 2018
StartActual
Jul 24, 2018
Primary completionActual
Jun 15, 2020
CompletionActual
Jun 15, 2020
Last update
Sep 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03604328
Lead sponsor
PolyActiva Pty Ltd
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Jul 24, 2018
Primary completion
Jun 15, 2020
Completion
Jun 15, 2020
Last update
Sep 16, 2020

Study contacts

Nathan Kerr
principal investigator · The Royal Victorian Eye & Ear Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA5108

Start the discussion